Compare Heron Therapeutics Inc (HRTX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sprott Uranium Miners ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Sprott Uranium Miners ETF trades at $46.46 (market cap $1.87B). The key difference: Sprott Uranium Miners ETF is far larger — about 27.5× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,586,926). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Sprott Uranium Miners ETF for 60 Days on average.
| HRTX | URNM | |
|---|---|---|
Market Cap | $68.01M | $1.87B |
Volume | 1,891,941 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.49 | $83.99 |
52-Week Low | $0.27 | $46.09 |
Typical Hold Time | 35 Days | 60 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
URNM (Sprott Uranium Miners ETF) trades at $47.87, down 4.83% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average indicators, though oscillators remain neutral. Recent news highlights uranium's long-term growth potential driven by AI energy demand and government nuclear investments, with spot uranium prices rising 21.25% over the past year according to Sprott Asset Management (September 2026).
The uranium sector shows strong fundamental tailwinds from nuclear energy expansion and AI power needs, but URNM's technical weakness suggests near-term volatility. Investment opportunity exists in uranium supply deficits and contracting growth, while risks include ETF concentration and commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
